UNSPSC 51362406: Homofenazine hydrochloride

This classification denotes a sedative and hypnotic with the molecular formula C23H28F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5JN11UQL, chemically known as 2-trifluoroethyl-10-(3-(4-(beta-hydroxyethyl-1-hexahydro-1,4-diazepinyl)propyl)phenothiazine but more generally known as homofenazine dihydrochloride, which bears US NIH Compound Identifier 19687. European Medicines Agency schedules Homofenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02537MIG.

Most nations, for tariff and trade purposes, schedule homofenazine hydrochloride under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCCN(CC4)CCO.CL.CL.

UNSPSC 51362406 Homofenazine hydrochloride is a Commodity code that in practice captures pharmaceutical procurement by state and local governments focused on emergency-response medications, opioid-overdose reversal agents, and generic multi-source drugs supplied through authorized wholesalers to health departments, community health facilities, and state employee benefit programs. The code's nominal scope and the recent solicitations show significant misalignment — the actual buying activity centers on naloxone, generic pharmaceutical formularies, and direct-to-manufacturer prescription programs rather than homofenazine hydrochloride specifically. State and local issuing bodies under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances serving state procurement offices and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance/MMCAP). The mix reflects both single-jurisdiction and multi-jurisdictional cooperative purchasing vehicles, with MMCAP representing the most structured and repeatable contracting approach across multiple states and local entities.

Recent activity is concentrated in Florida and across the multistate MMCAP footprint (Minnesota, Oregon, and participating jurisdictions). Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through competitive bidding with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness set for July 1, 2026, and pricing weighted at 75 percent of evaluation. No explicit set-asides or disadvantaged-enterprise restrictions appear in the source materials across these solicitations.